U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Wed Apr 02 14:21:39 GMT 2025
Edited
by admin
on Wed Apr 02 14:21:39 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1|TOXIN CONJUGATE
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
VHA6L8H5FM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Becotatug Vedotin
INN  
Official Name English
MRG-003
Preferred Name English
Anti-EGFR Antibody-drug Conjugate MRG003
Common Name English
MRG003
Code English
Immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, compri
Common Name English
H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV4-4*08 (79.4%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342
Common Name English
antibody drug conjugate (ADC) composed of a recombinant humanized anti-human Epidermal growth factor receptor (EGFR) monoclonal antibody JMT101 conjugated with the cytotoxic small molecule MMAE
Common Name English
Recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E
Common Name English
Anti-EGFR ADC MRG003
Common Name English
becotatug vedotin [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 899622
Created by admin on Wed Apr 02 14:21:39 GMT 2025 , Edited by admin on Wed Apr 02 14:21:39 GMT 2025
Code System Code Type Description
INN
13230
Created by admin on Wed Apr 02 14:21:39 GMT 2025 , Edited by admin on Wed Apr 02 14:21:39 GMT 2025
PRIMARY
SMS_ID
300000056826
Created by admin on Wed Apr 02 14:21:39 GMT 2025 , Edited by admin on Wed Apr 02 14:21:39 GMT 2025
PRIMARY
FDA UNII
VHA6L8H5FM
Created by admin on Wed Apr 02 14:21:39 GMT 2025 , Edited by admin on Wed Apr 02 14:21:39 GMT 2025
PRIMARY
NCI_THESAURUS
C180585
Created by admin on Wed Apr 02 14:21:39 GMT 2025 , Edited by admin on Wed Apr 02 14:21:39 GMT 2025
PRIMARY
CAS
2770851-80-2
Created by admin on Wed Apr 02 14:21:39 GMT 2025 , Edited by admin on Wed Apr 02 14:21:39 GMT 2025
PRIMARY
From To
1_22 1_95
2_22 2_95
2_146 2_202
2_222 4_214
2_263 2_323
1_146 1_202
2_369 2_427
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
1_222 3_214
1_228 2_228
1_231 2_231
1_263 1_323
1_369 1_427
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_299
N 2_299
Related Record Type Details
CONJUGATE COMPONENT->CONJUGATE
CONJUGATE COMPONENT->CONJUGATE
TARGET->CONJUGATED TOXIN
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION RESIDUE_SPECIFIC C Amount: Cysteinyl vedotin 6603L01WUR
AMINO ACID REMOVAL [1_449] [2_449] C-TERMINUS LYSINE K3Z4F929H6
AMINO_ACID_SUBSTITUTION [1_1] [2_1] N-TERMINUS Q PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL